CD226 and melanoma: Julien et al. indicated that a high TIGIT/CD226 ratio in Tregs regulates their suppressive function and stability in melanoma, and they suggested novel immunotherapies to activate CD226 in Tregs together with TIGIT blockade to counteract Treg suppression in cancer patients (Fourcade et al., 2018).